RAD001 Shows Potential To Reverse Resistance To Herceptin(R) In Metastatic Breast Can

[News]

New data from two early clinical studies show that RAD001(R) (everolimus) may overcome resistance to Herceptin(R) (trastuzumab) in women with HER2-positive metastatic breast cancer. These results support the initiation of a Phase III clinical trial program to fully explore the potential of RAD001 (proposed brand name Afinitor(R)) in breast cancer. Two Phase I studies were presented today during the CTRC-AACR San Antonio Breast Cancer Symposium.

More... (http://www.medicalnewstoday.com/articles/132915.php)